Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more
Biotechs, academics turn to partnerships to overcome manufacturing barriers to gene and cell therapies
Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply.
At least seven manufacturing deals and site launches in January underscore different techniques companies and academics are employing in order to break through the capacity constraints for gene and cell therapies.
On Thursday, Deerfield Management and The Discovery Labs launched a contract development and manufacturing organization that will provide preclinical through commercial manufacturing of cell and gene therapies, as well as component raw materials.
According to the partners, the CDMO,